DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION				
DISTRICT ADDRESS AND PHONE NUMBER			DATE(S) OF INSPECTION	
US Customhouse Rm900 2nd & Chestnut St			017-6/6/2017*	
Philadelphia, PA 19106 (215)597-4390 Ext:4200 Fax:(215)597-0875		FEI NUMBER		
(215)597-4590 EXC.4200 Fax.(215)597-0675				
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED				
Martin J. Garda , President and Owner				
Garda Rx LLC		1596 Hancock Ave		
CITY, STATE, ZIP CODE, COUNTRY		TYPE ESTABLISHMENT INSPECTED		
Apollo, PA 15613-8404		Producer of Non-Sterile Drugs		
This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above.				
DURING AN INSPECTION OF YOUR FIRM I OBSERVED: <u>Insanitary Conditions</u>				
I observed the process of producing non-sterile products at Garda Rx, LLC and found that:				
• The(b) (4) counter top used for the production of non-sterile drug products had exposed particle board on a side adjacent to the work surface.				
• Visible residues and filth adjacent to the non-sterile production area on places such as:				
• Shelf with non-sterile production equipment.				
• On the balance used for production of non-sterile drug products.				
• In the (b) (4) use for production of non-sterile drug products.				
*DATES OF INSPECTION 6/01/2017(Thu),6/02/2017(Fri),6/05/2017(Mon),6/06/2017(Tue)				
EMPLOYEE(S) SIGNATURE DATE ISSUED				
SEE REVERSE OF THIS PAGE	Juan R Jimenez Garcia, Inves	tigator	665/2017 Xuan R. Immerz Garcia Immestigator Sipped by Xuan R. Immenz Garcia -S	6/6/2017
FORM FDA 483 (09/08) PREVIOUS EDITION OBSOLETE INSPECTIONAL OBSERVATIONS P			PAGE 1 OF 2 PAGES	